Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick R Verhoest

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Journal of Medicinal Chemistry|September 29, 2017
The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) ImagingLei Zhang, Laigao Chen, Elizabeth M Beck, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing InteractionsJamison B Tuttle, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry|January 17, 2014
Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulatorsMartin Pettersson, Douglas S Johnson, Chakrapani Subramanyam, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic StabilityMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Medchemcomm|August 16, 2018
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacyMartin Pettersson, Douglas S Johnson, Danica A Rankic, et al.
Journal of Medicinal Chemistry|June 3, 2017
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A InhibitorChristopher J Helal, Eric P Arnold, Tracey L Boyden, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Journal of Medicinal Chemistry|September 29, 2017
The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) ImagingLei Zhang, Laigao Chen, Elizabeth M Beck, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing InteractionsJamison B Tuttle, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry|January 17, 2014
Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulatorsMartin Pettersson, Douglas S Johnson, Chakrapani Subramanyam, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic StabilityMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Medchemcomm|August 16, 2018
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacyMartin Pettersson, Douglas S Johnson, Danica A Rankic, et al.
Journal of Medicinal Chemistry|June 3, 2017
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A InhibitorChristopher J Helal, Eric P Arnold, Tracey L Boyden, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.
Pageof 4